The evaluation of program death 1 and PD-1 ligand expressions in histological subtypes of primary extranodal non hodgkin lymphoma
Introduction: Emergence of Programmed death 1 (PD-1) and its ligands, PD-L1 immunotherapy provide new insight in the treatment modality of malignancies. The responsiveness of the patients are associated with the expressions of the PD-L1 and PD-1 protein. We aimed to evaluate the expression of PD-...
Saved in:
| Main Author: | |
|---|---|
| Format: | Thesis |
| Language: | English |
| Published: |
2021
|
| Subjects: | |
| Online Access: | http://eprints.usm.my/58572/1/FARHANA%20MOHAMMAD%20MOHAIDIN-24%20pages.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction: Emergence of Programmed death 1 (PD-1) and its ligands, PD-L1 immunotherapy
provide new insight in the treatment modality of malignancies. The responsiveness of the patients
are associated with the expressions of the PD-L1 and PD-1 protein. We aimed to evaluate the
expression of PD-1 in the tumour microenvironment and PD-L1 in the tumour cells with
histological subtypes of primary extranodal non-Hodgkin lymphoma (peNHL).
Methodology: A retrospective cross-sectional study using 87 archived formalin fixed paraffin-embedded
tissue blocks of patients diagnosed with peNHL. Samples were stained for PD-1 and
PD-L1 by immunohistochemistry method and the proteins expressions were evaluated
microscopically. The association between expression of the PD-1 and PD-L1 with subtypes of
peNHL were statistically analysed.
Results: Majority of the cases are negative expression of PD-L1 in the tumour cells (46, 52.9%),
however majority are positive for PD-1 expression in the tumour microenvironment (57, 65.5%).
Significant associations were found between PD-1 and PD-L1 expression with subtypes of peNHL
(p<0.05) and higher expression was found in DLBCL.
Conclusion: Our study, the first in Malaysia to explore expression of PD-1 and PD-L1 in peNHL,
demonstrates significant association of PD-1 and PD-L1 expressions with subtypes of peNHL
which may impact treatment of these patients in the future. |
|---|